Anti-inflammatory activity of roflumilast: Study on the efficacy of oral roflumilast (500 μg/d) over 4 weeks on sputum eosinophils in patients with asthma. A double-blind randomized placebo-controlled parallel group study
Study Complete
Official Title
*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].
Medical condition
asthma
Phase
Phase 2
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
42
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Mar 2001
Primary Completion Date: -
Study Completion Date: 01 Sept 2004
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jun 2016 by Takeda
Sponsors
Takeda
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
